Oral controlled release dosage form

• US 8,252,327 B2
• Filed: 07/11/2011
• Issued: 08/28/2012
• Est. Priority Date: 12/09/2002
• Status: Expired due to Fees

• Current Assignee: Andrx Pharmaceuticals (NC), Inc. (Abbvie Incorporated)
• Original Assignee: Andrx Pharmaceuticals (NC), Inc. (Abbvie Incorporated)
• Inventors: Dixit, Manesh, Cheng, Xiu-Xiu, Xie, Jianbo, Chen, Chih-Ming
• Primary Examiner(s): CLAYTOR, DEIRDRE RENEE
• Application Number:
  US13/179,830
• Publication Number:
  US 20110268799A1
• Time in Patent Office: 414 Days
• Field of Search: 424/452, 424/469
• US Class Current: 424/452
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system

Abstract

A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.

Claims

1. A controlled release methylphenidate tablet consisting of:

(A) an immediate release methylphenidate coating consisting of;

(a) 30-60 weight percent based upon the total weight of the immediate release coating of methylphenidate or a pharmaceutically acceptable salt or isomer thereof;

(b) 40-70 weight percent based upon the total weight of the immediate release coating of a binder; and

(c) 0.005-5 weight percent based upon the total weight of the immediate release coating of an organic acid;

(B) a controlled release methylphenidate core tablet consisting of;

(a) a compressed mixture consisting of;

(i) 5-40 weight percent based upon the total weight of the compressed mixture of methylphenidate or a pharmaceutically acceptable salt or isomer thereof;

(ii) 3-40 weight percent based upon the total weight of the compressed mixture of a hydrogel polymer;

(iii) 25-90 weight percent based upon the total weight of the compressed mixture of a diluent; and

(iv) optionally a lubricant; and

(b) an enteric coating surrounding the core tablet consisting of;

(i) 10-70 weight percent based upon the total weight of the enteric coating of a methacrylic acid copolymer;

(ii) 1-5 weight percent based upon the total weight of the enteric coating of a plasticizer;

(iii) an anti-sticking agent; and

(iv) optionally a surfactant; and

(C) optionally an aesthetic coating;

wherein the controlled release methylphenidate tablet exhibits the following dissolution profile when tested in a United States Pharmacopeia type 2 (paddle) apparatus at 50 rpms in 900 ml of phosphate buffer with a pH of 7.5 and at 37°

C.;

1-35% of the methylphenidate is released after 1 hour;

5-40% of the methylphenidate is released after 2 hours; and

not less than 70% is release after 10 hours; and

when administered to humans exhibits a plasma peak for the immediate release layer (T_max1) between 1 and 5 hours, a plasma peak for the controlled release core (T_max2) between 4 and 12 hours, and a plasma trough (T_min) between 2 and 7 hours in between the two peak plasma levels; and

wherein the immediate release methylphenidate coating (A) is applied to the enteric coating surrounding the core tablet.

2. The controlled release methylphenidate tablet as defined in claim 1 wherein:

(A) the immediate release methylphenidate coating consists of;

(a) 40-50 weight percent based upon the total weight of the immediate release coating of methylphenidate or a pharmaceutically acceptable salt or isomer thereof;

(b) 45-60 weight percent based upon the total weight of the immediate release coating of a binder; and

(c) 0.01-2 weight percent based upon the total weight of the immediate release coating of an organic acid; and

(B) the controlled release methylphenidate core tablet consists of;

(a) a compressed mixture consisting of;

(i) 10-25 weight percent based upon the total weight of the compressed mixture of methylphenidate or a pharmaceutically acceptable salt or isomer thereof;

(ii) 3-40 weight percent based upon the total weight of the compressed mixture of a hydrogel polymer;

(iii) 45-85 weight percent based upon the total weight of the compressed mixture of a diluent; and

(iv) 0.1-10 weight percent based upon the total weight of the compressed mixture of a lubricant.

3. The controlled release methylphenidate tablet as defined in claim 1 wherein the binder employed in the immediate release coating is hydroxypropyl methylcellulose.

4. The controlled release methylphenidate tablet as defined in claim 3 wherein the T_max2 occurs about 7 to 9 hours and declines to about 1.4 ng/ml in about 14 to 18 hours.

5. The controlled release methylphenidate tablet of claim 2 wherein the compressed mixture of the core tablet consists of 0.5-5 weight percent based upon the total weight of the compressed mixture of a lubricant.

6. The controlled release methylphenidate tablet as defined in claim 1 where the diluent is selected from the group consisting of sugars, starches or vegetable oils, lactose monohydrate, calcium phosphate, dextrin, dextrose, maltitol, maltose, starch, sucrose or talc.

7. The controlled release methylphenidate tablet as defined in claim 1 wherein said diluent comprises lactose monohydrate.

8. The controlled release methylphenidate tablet as defined in claim 1 where the hydrogel polymer in the core is selected from the group consisting of methyl cellulose, hydroxymethyl cellulose, polyvinyl pyrrolidone, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene oxides, gums, acrylate polymers and methacrylate polymers.

9. The controlled release methylphenidate tablet as defined in claim 1 wherein the hydrogel polymer in the core is hydroxypropyl methylcellulose.

10. The controlled release methylphenidate tablet as defined in claim 2 where the anti-sticking agent is selected from the group consisting of talc, glyceryl monostearates, calcium stearate, magnesium stearate, stearic acid, glyceryl behenate, and polyethylene glycol.

11. The controlled release methylphenidate tablet as defined in claim 1 wherein said anti-sticking agent comprises talc.

12. The controlled release methylphenidate tablet as defined in claim 1 wherein the plasticizer is selected from a group consisting of acetyltributyl citrate, triacetin, acetylated monoglyceride, coconut oil, poloxamer, acetyltriethyl citrate, glycerin sorbitol, diethyloxalate, diethylmalate, diethylfumerate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylphthalate, dibutylsebacate, triethyl citrate, tributylcitrate, glyceroltributyrate, polyethylene glycol, propylene glycol and mixtures thereof.

13. The controlled release methylphenidate tablet as defined in claim 12 wherein the plasticizer is acetyltributyl citrate.